Comparison of long-acting analogues of luteinizing hormone releasing hormone in man

J. A H Wass, G. M. Besser, A. Gomez-Pan, M. F. Scanlon, R. Hall, A. J. Kastin, D. H. Coy, Andrew V Schally

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Currently, LHRH, when used therapeutically, is given by parenteral injection every 8 h. We have looked at the release of LH and FSH induced by five analogues of LHRH and compared this with gonadotrophin release after synthetic LHRH. The analogues were substituted in position 6 or in positions 6 and 10 and were given intravenously, intranasally or subcutaneously in three separate studies. After intravenous administration of 100 μg, all analogues caused greater release of LH and FSH than did synthetic LHRH. Given intranasally in a dose of 500 μg, three of the four analogues tested caused greater LH and FSH release than did LHRH. With tryptophan substitution in position 6 (D-TRP6-LHRH), mean LH levels in five subjects were still above the normal range 24 h after a single intranasal dose. The intranasal administration of selected analogues of LHRH has great potential in the treatment of conditions associated with deficient gonadotrophin secretion, provided that pituitary overstimulation, which may eventually lead to a decrease in LH and FSH output by the anterior pituitary, is avoided.

Original languageEnglish
Pages (from-to)419-430
Number of pages12
JournalClinical Endocrinology
Volume10
Issue number4
StatePublished - Dec 1 1979
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Gonadotropins
Intranasal Administration
Tryptophan
Intravenous Administration
Reference Values
Injections

ASJC Scopus subject areas

  • Endocrinology

Cite this

Wass, J. A. H., Besser, G. M., Gomez-Pan, A., Scanlon, M. F., Hall, R., Kastin, A. J., ... Schally, A. V. (1979). Comparison of long-acting analogues of luteinizing hormone releasing hormone in man. Clinical Endocrinology, 10(4), 419-430.

Comparison of long-acting analogues of luteinizing hormone releasing hormone in man. / Wass, J. A H; Besser, G. M.; Gomez-Pan, A.; Scanlon, M. F.; Hall, R.; Kastin, A. J.; Coy, D. H.; Schally, Andrew V.

In: Clinical Endocrinology, Vol. 10, No. 4, 01.12.1979, p. 419-430.

Research output: Contribution to journalArticle

Wass, JAH, Besser, GM, Gomez-Pan, A, Scanlon, MF, Hall, R, Kastin, AJ, Coy, DH & Schally, AV 1979, 'Comparison of long-acting analogues of luteinizing hormone releasing hormone in man', Clinical Endocrinology, vol. 10, no. 4, pp. 419-430.
Wass JAH, Besser GM, Gomez-Pan A, Scanlon MF, Hall R, Kastin AJ et al. Comparison of long-acting analogues of luteinizing hormone releasing hormone in man. Clinical Endocrinology. 1979 Dec 1;10(4):419-430.
Wass, J. A H ; Besser, G. M. ; Gomez-Pan, A. ; Scanlon, M. F. ; Hall, R. ; Kastin, A. J. ; Coy, D. H. ; Schally, Andrew V. / Comparison of long-acting analogues of luteinizing hormone releasing hormone in man. In: Clinical Endocrinology. 1979 ; Vol. 10, No. 4. pp. 419-430.
@article{58780e596fe44387bdedc956bb3e9cbb,
title = "Comparison of long-acting analogues of luteinizing hormone releasing hormone in man",
abstract = "Currently, LHRH, when used therapeutically, is given by parenteral injection every 8 h. We have looked at the release of LH and FSH induced by five analogues of LHRH and compared this with gonadotrophin release after synthetic LHRH. The analogues were substituted in position 6 or in positions 6 and 10 and were given intravenously, intranasally or subcutaneously in three separate studies. After intravenous administration of 100 μg, all analogues caused greater release of LH and FSH than did synthetic LHRH. Given intranasally in a dose of 500 μg, three of the four analogues tested caused greater LH and FSH release than did LHRH. With tryptophan substitution in position 6 (D-TRP6-LHRH), mean LH levels in five subjects were still above the normal range 24 h after a single intranasal dose. The intranasal administration of selected analogues of LHRH has great potential in the treatment of conditions associated with deficient gonadotrophin secretion, provided that pituitary overstimulation, which may eventually lead to a decrease in LH and FSH output by the anterior pituitary, is avoided.",
author = "Wass, {J. A H} and Besser, {G. M.} and A. Gomez-Pan and Scanlon, {M. F.} and R. Hall and Kastin, {A. J.} and Coy, {D. H.} and Schally, {Andrew V}",
year = "1979",
month = "12",
day = "1",
language = "English",
volume = "10",
pages = "419--430",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Comparison of long-acting analogues of luteinizing hormone releasing hormone in man

AU - Wass, J. A H

AU - Besser, G. M.

AU - Gomez-Pan, A.

AU - Scanlon, M. F.

AU - Hall, R.

AU - Kastin, A. J.

AU - Coy, D. H.

AU - Schally, Andrew V

PY - 1979/12/1

Y1 - 1979/12/1

N2 - Currently, LHRH, when used therapeutically, is given by parenteral injection every 8 h. We have looked at the release of LH and FSH induced by five analogues of LHRH and compared this with gonadotrophin release after synthetic LHRH. The analogues were substituted in position 6 or in positions 6 and 10 and were given intravenously, intranasally or subcutaneously in three separate studies. After intravenous administration of 100 μg, all analogues caused greater release of LH and FSH than did synthetic LHRH. Given intranasally in a dose of 500 μg, three of the four analogues tested caused greater LH and FSH release than did LHRH. With tryptophan substitution in position 6 (D-TRP6-LHRH), mean LH levels in five subjects were still above the normal range 24 h after a single intranasal dose. The intranasal administration of selected analogues of LHRH has great potential in the treatment of conditions associated with deficient gonadotrophin secretion, provided that pituitary overstimulation, which may eventually lead to a decrease in LH and FSH output by the anterior pituitary, is avoided.

AB - Currently, LHRH, when used therapeutically, is given by parenteral injection every 8 h. We have looked at the release of LH and FSH induced by five analogues of LHRH and compared this with gonadotrophin release after synthetic LHRH. The analogues were substituted in position 6 or in positions 6 and 10 and were given intravenously, intranasally or subcutaneously in three separate studies. After intravenous administration of 100 μg, all analogues caused greater release of LH and FSH than did synthetic LHRH. Given intranasally in a dose of 500 μg, three of the four analogues tested caused greater LH and FSH release than did LHRH. With tryptophan substitution in position 6 (D-TRP6-LHRH), mean LH levels in five subjects were still above the normal range 24 h after a single intranasal dose. The intranasal administration of selected analogues of LHRH has great potential in the treatment of conditions associated with deficient gonadotrophin secretion, provided that pituitary overstimulation, which may eventually lead to a decrease in LH and FSH output by the anterior pituitary, is avoided.

UR - http://www.scopus.com/inward/record.url?scp=0018643677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018643677&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 419

EP - 430

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 4

ER -